http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
‘‘Anode-free” Zn/LiFePO4 aqueous batteries boosted by hybrid electrolyte
Jingying Duan,Luofu Min,Mengqian Wu,Ting Yang,Mingming Chen,Chengyang Wang 한국공업화학회 2022 Journal of Industrial and Engineering Chemistry Vol.114 No.-
Aqueous rechargeable batteries with Zn as anode directly have become prospective alternatives to conventionallithium-ion batteries. However, the growth of zinc dendrites restricts the practical applicationof Zn anode greatly. In addition, the use of thick zinc foil as anode also increases the total weight of thebattery and impacts the whole energy density. Herein, a kind of ‘‘anode-free” Zn/LiFePO4 battery (zeroexcessZn) is designed to solve such problems, and corresponding electrolyte is optimized to ensurethe electrochemical performance. As a result, ethylene glycol (EG) is added to the aqueous electrolytewith 1.5 M Zn(CF3SO3)2 and 1.5 M LiCF3SO3 as solutes, which not only improves the stability of the electrolyte,but also inhibits the growth of zinc dendrites. And the Zn/Cu batteries with 70 vol% EG/H2Ohybrid electrolyte show highly reversible Zn plating/stripping process, in which the average coulombicefficiency (ACE) is as high as 99.77 % at a current density of 1 mA cm2. In order to better adapt to the‘‘anode-free” Zn/LiFePO4 battery system, the ratio of Zn2+ to Li+ ions in this electrolyte is further optimized,and it’s found that the battery with 2 M Zn(CF3SO3)2 + 1 M LiCF3SO3-70 vol% EG/H2O electrolyteshows the most excellent electrochemical stability, in which the capacity retention rate is 75.2 % after100 cycles at a current density of 1 mA cm2. Our work makes it possible for the application of aqueous‘‘anode-free” batteries.
Ran Chu,Penglin Liu,Jingying Chen,Xiaodong Cheng,Kezhen Li,Yanci Che,Jianliu Wang,Li Li,Xi Zhang,Shu Yao,Li Song,Ying Zhao,Changzhen Huang,Ying Xue,Xiyu Pan,Junting Li,Zhongshao Chen,Jie Jiang,Beihua 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.2
Objective: To evaluate the impact of bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (PC) chemotherapy regimens on the fertility and prognostic outcomes in malignant ovarian germ cell tumor (MOGCT) patients who underwent fertility-sparing surgery (FSS). Methods: A propensity score matching algorithm was performed between the BEP and PC groups. The χ2 test and the Kaplan-Meier method were used to compare the fertility outcome, disease-free survival (DFS) and overall survival (OS). The Cox proportional hazards regression analysis was used to identify risk factor of DFS. Results: We included 213 patients, 185 (86.9%) underwent BEP chemotherapy, and 28 (13.1%) underwent PC chemotherapy. The median age was 22 years (range, 8–44 years), and the median follow-up period was 63 months (range, 2–191 months). Fifty-one (29.3%) patients had a pregnancy plan, and 35 (85.4%) delivered successfully. In the before and after propensity score matching cohorts, there were no significant differences in spontaneous abortion, selective termination of pregnancy, during-pregnancy status, and live birth between the BEP and PC groups (p>0.05). Fourteen (6.6%) patients experienced recurrence, including 11 (5.9%) in the BEP group and 3 (10.7%) in the PC group. Four (1.9%) patients in the BEP group died. Kaplan-Meier analysis revealed no significant differences in DFS (p=0.328) and OS (p=0.446) between the BEP and PC groups, and the same survival results were observed in the after matching cohort. Conclusion: The PC regimen is as safe as the BEP regimen for MOGCT patients with fertility preservation treatment, and no differences were observed in fertility and clinical prognosis.
High-Mobility Bismuth-based Transparent <i>p</i>-Type Oxide from High-Throughput Material Screening
Bhatia, Amit,Hautier, Geoffroy,Nilgianskul, Tan,Miglio, Anna,Sun, Jingying,Kim, Hyung Joon,Kim, Kee Hoon,Chen, Shuo,Rignanese, Gian-Marco,Gonze, Xavier,Suntivich, Jin American Chemical Society 2016 Chemistry of materials Vol.28 No.1
Shi Si,Gu Huijie,Xu Jinyuan,Sun Wan,Liu Caiyin,Zhu Tong,Wang Juan,Gao Furong,Zhang Jieping,Ou Qingjian,Jin Caixia,Xu Jingying,Chen Hao,Li Jiao,Xu Guotong,Tian Haibin,Lu Lixia 생화학분자생물학회 2023 Experimental and molecular medicine Vol.55 No.-
Excessive osteoclast activation, which depends on dramatic changes in actin dynamics, causes osteoporosis (OP). The molecular mechanism of osteoclast activation in OP related to type 1 diabetes (T1D) remains unclear. Glia maturation factor beta (GMFB) is considered a growth and differentiation factor for both glia and neurons. Here, we demonstrated that Gmfb deficiency effectively ameliorated the phenotype of T1D-OP in rats by inhibiting osteoclast hyperactivity. In vitro assays showed that GMFB participated in osteoclast activation rather than proliferation. Gmfb deficiency did not affect osteoclast sealing zone (SZ) formation but effectively decreased the SZ area by decreasing actin depolymerization. When GMFB was overexpressed in Gmfb-deficient osteoclasts, the size of the SZ area was enlarged in a dose-dependent manner. Moreover, decreased actin depolymerization led to a decrease in nuclear G-actin, which activated MKL1/SRF-dependent gene transcription. We found that pro-osteoclastogenic factors (Mmp9 and Mmp14) were downregulated, while anti-osteoclastogenic factors (Cftr and Fhl2) were upregulated in Gmfb KO osteoclasts. A GMFB inhibitor, DS-30, targeting the binding site of GMFB and Arp2/3, was obtained. Biocore analysis revealed a high affinity between DS-30 and GMFB in a dose-dependent manner. As expected, DS-30 strongly suppressed osteoclast hyperactivity in vivo and in vitro. In conclusion, our work identified a new therapeutic strategy for T1D-OP treatment. The discovery of GMFB inhibitors will contribute to translational research on T1D-OP.